NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Actuate Therapeutics Inc.
Fluidx Medical Technology, Inc.
Institute of Mother and Child, Warsaw, Poland
M.D. Anderson Cancer Center
UMC Utrecht
Memorial Sloan Kettering Cancer Center